此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项针对复发/难治性非霍奇金淋巴瘤的TORL-5-700研究

2026年9月24日 更新者:TORL Biotherapeutics, LLC

一项针对复发或难治性非霍奇金淋巴瘤参与者的TORL-5-700单药及联合用药的1/2期、首次人体、开放标签、多中心研究

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL

研究概览

研究类型

介入性

注册 (估计的)

155

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • California
      • Fullerton、California、美国、92835
        • 招聘中
        • Providence Medical Foundation
      • Los Alamitos、California、美国、90720
        • 招聘中
        • Cancer and Blood Specialty Clinic, Los Alamitos
      • Santa Monica、California、美国、90404
        • 招聘中
        • UCLA
      • Stanford、California、美国、94305
        • 招聘中
        • Stanford University
    • Florida
      • Miami、Florida、美国、33136
        • 招聘中
        • University of California Miami, Sylvester Comprehensive Cancer Center
    • Iowa
      • Iowa City、Iowa、美国、52242
        • 招聘中
        • University of Iowa Health Care
    • Kansas
      • Wichita、Kansas、美国、67214
        • 招聘中
        • Cancer Center of Kansas, Wichita
    • Tennessee
      • Nashville、Tennessee、美国、37203
        • 招聘中
        • Sarah Cannon Research Institute
    • Texas
      • Dallas、Texas、美国、75390
        • 招聘中
        • University of Texas Southwestern Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT.
  • Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
  • At least 1 measurable lesion per Lugano criteria.
  • Tumor tissue is available.
  • Adequate organ function

Exclusion Criteria:

  • T-cell lymphoma
  • CLL or SL
  • Burkitt lymphoma and high-grade B-cell lymphoma
  • CNS involvement
  • Peripheral neuropathy > Grade 2
  • Uncontrolled medical conditions
  • Viral infections

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Part 1: Monotherapy Dose Escalation

TORL-5-700 Administered once every three weeks

Part 1: Monotherapy Dose Escalation - TORL-5-700 Administered once every three weeks

实验性的:Part 2: Monotherapy Expansion

TORL-5-700 at MTD/RP2D Administered once every three weeks

Part 2: Monotherapy Expansion - TORL-5-700 at Maximum tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) Administered once every three weeks

实验性的:Part 3: Combination Evaluation

TORL-5-700 at MTD/RP2D Administered once every three weeks in combination with another agent

Part 3: Combination Evaluation - TORL-5-700 at MTD/RP2D administered every three weeks in combination with another agent

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Evaluate the safety of TORL-5-700 as a monotherapy
大体时间:though study completion, an average of 2.5 years

Assessment of adverse events according to NCI-CTCAE Version 5.0

though study completion, an average of 2.5 years
Assess the antitumor activity of TORL-5-700 as monotherapy
大体时间:though study completion, an average of 2.5 years

Assess the antitumor activity of TORL-5-700 using Cheson (2014) disease grading criteria

though study completion, an average of 2.5 years
Evaluate the safety of TORL-5-700 in combination with other agents
大体时间:though study completion, an average of 2.5 years

Assessment of adverse events according to NCI-CTCAE Version 5.0

though study completion, an average of 2.5 years
Determine the Maximum Tolerated Dose (MTD)
大体时间:21 days from the start of treatment

Determine the MTD by assessing Protocol defined Dose Limiting Toxicities (DLT)

21 days from the start of treatment
Determine the Recommended Phase 2 Dose (RP2D)
大体时间:21 days from the start of treatment

Determine the RP2D by assessing Protocol defined Dose Limiting Toxicities

21 days from the start of treatment

次要结果测量

结果测量
措施说明
大体时间
Maximum Serum Concentration of TORL-5-700 (Cmax)
大体时间:though end of study treatment, an average of 5 months

Pk assessment

though end of study treatment, an average of 5 months
Maximum Serum Concentration of TORL-5-700 (Cmax) in combination with other agents
大体时间:though end of study treatment, an average of 5 months

Pk assessment

though end of study treatment, an average of 5 months
Terminal Half-life (t1/2) of Serum TORL-5-700
大体时间:though end of study treatment, an average of 5 months

Pk assessment

though end of study treatment, an average of 5 months
Terminal Half-life (t1/2) of Serum TORL-5-700 in combination with other agents
大体时间:though end of study treatment, an average of 5 months

Pk assessment

though end of study treatment, an average of 5 months
Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration
大体时间:though end of study treatment, an average of 5 months

Pk assessment

though end of study treatment, an average of 5 months
Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration in combination with other agents
大体时间:though end of study treatment, an average of 5 months

Pk assessment

though end of study treatment, an average of 5 months
Clearance (CL) of TORL-5-700
大体时间:though end of study treatment, an average of 5 months

Pk assessment

though end of study treatment, an average of 5 months
Clearance (CL) of TORL-5-700 in combination with other agents
大体时间:though end of study treatment, an average of 5 months

Pk assessment

though end of study treatment, an average of 5 months
Volume of distribution of TORL-5-700
大体时间:though end of study treatment, an average of 5 months

PK assessment

though end of study treatment, an average of 5 months
Volume of distribution of TORL-5-700 in combination with other agents
大体时间:though end of study treatment, an average of 5 months

PK assessment

though end of study treatment, an average of 5 months
Immunogenicity of TORL-5-700
大体时间:though end of study treatment, an average of 5 months

Immunogenicity will be measured by incidence of treatment emergent ADAs

though end of study treatment, an average of 5 months
Immunogenicity of TORL-5-700 in combination with other agents
大体时间:though end of study treatment, an average of 5 months

Immunogenicity will be measured by incidence of treatment emergent ADAs

though end of study treatment, an average of 5 months
Assess the preliminary antitumor activity of TORL-5-700 in combination with other agents
大体时间:though study completion, an average of 2.5 years

Assess the antitumor activity of TORL-5-700 in combination with other agents using Cheson (2014) disease grading criteria

though study completion, an average of 2.5 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年3月31日

初级完成 (估计的)

2029年3月31日

研究完成 (估计的)

2029年9月30日

研究注册日期

首次提交

2026年2月10日

首先提交符合 QC 标准的

2026年2月23日

首次发布 (实际的)

2026年2月27日

研究记录更新

最后更新发布 (实际的)

2026年9月28日

上次提交的符合 QC 标准的更新

2026年9月24日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅